Cigna's Evernorth Eliminates Prior Authorization for TMS, Boosting BrainsWay Access

summarizeSummary

BrainsWay announced that Cigna's Evernorth Behavioral Health will eliminate prior authorization requirements for transcranial magnetic stimulation (TMS) coverage, effective March 6, 2026, significantly expanding patient access to BrainsWay's Deep TMS systems.

check_boxKey Events · Product Development and Regulatory · BWAY

• Prior Authorization Eliminated

  Cigna's Evernorth Behavioral Health, a division of the Cigna Group serving over 18 million lives, will no longer require prior authorization for transcranial magnetic stimulation (TMS) for contracted providers.

• Expanded Patient Access

  This change, effective March 6, 2026, is expected to significantly accelerate patient access to TMS treatment for major depressive disorder and obsessive-compulsive disorder, directly benefiting BrainsWay's Deep TMS systems.

• Reinforces Positive Market Trend

  This decision continues a recent trend of major insurers expanding coverage and easing access to TMS, following similar announcements from Highmark Blue Cross Blue Shield and Premera Blue Cross Blue Shield.

auto_awesomeAnalysis · BWAY · Industrial Applications And Services

This development is highly positive for BrainsWay as Cigna's Evernorth Behavioral Health, serving over 18 million lives, will eliminate a significant administrative barrier for transcranial magnetic stimulation (TMS) treatment. The removal of prior authorization requirements for contracted providers is expected to accelerate patient access to BrainsWay's Deep TMS systems for major depressive disorder and obsessive-compulsive disorder. This follows a series of recent positive coverage announcements from other major insurers, reinforcing a favorable trend for TMS adoption and BrainsWay's market penetration.